查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
精密精神醫學的全球市場 - 產業規模，佔有率，趨勢，機會，預測:各生物標記，各樣品，各技術，各用途，各終端用戶，各企業，各地區(2017年～2027年)
市場調查報告書
商品編碼
1152254

精密精神醫學的全球市場 - 產業規模，佔有率，趨勢，機會，預測:各生物標記，各樣品，各技術，各用途，各終端用戶，各企業，各地區(2017年～2027年)

Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Biomarkers, By Sample, By Technology, By Application, By End User, By Company and By Region
出版日期: | 出版商: TechSci Research | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球精密精神醫學的市場規模，在預測期間內的2023年～2027年預計達成驚人的成長。

市場成長的主要原因，是精神疾病發病率的上升和技術進步，推動全球市場成長。支撐市場成長的其他因素，是認識度的提高，投資擴大，人口增加，生活方式的變化，序列成本低，無機成長策略的採用增加政府對醫療基礎設施的，的支援等。還有進行精神疾病發病和徵兆相關的基因、蛋白質體學分析的研究人員對先進分子診斷技術高的引進率，也是推動市場成長的主要原因。

本報告提供全球精密精神醫學市場相關調查分析，各市場區隔、各地區的市場規模、佔有率預測，市場動態，企業簡介等系統性資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 COVID-19對全球精密精神醫學市場的影響

第5章 VOC(客戶的迴響)

第6章 全球精密精神醫學市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各生物標記(遺傳基因和蛋白質)
    • 各樣品(血液為基礎和血液為基礎以外)
    • 各技術(定序，聚合酵素鏈鎖反應，微陣列，免疫測量，其他)
    • 各用途(阿茲海默症，帕金森氏症，自閉症，憂鬱症，其他)
    • 各終端用戶(醫院、診所，學術、調查機關，其他)
    • 各企業(2021年)
    • 各地區
  • 產品市場地圖

第7章 北美的精密精神醫學市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各生物標記
    • 各樣品
    • 各技術
    • 各用途
    • 各終端用戶
    • 各國
  • 北美:各國分析
    • 美國
    • 墨西哥
    • 加拿大

第8章 歐洲的精密精神醫學市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各生物標記
    • 各樣品
    • 各技術
    • 各用途
    • 各終端用戶
    • 各國
  • 歐洲:各國分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章 亞太地區的精密精神醫學市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各生物標記
    • 各樣品
    • 各技術
    • 各用途
    • 各終端用戶
    • 各國
  • 亞太地區:各國分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第10章 南美的精密精神醫學市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各生物標記
    • 各樣品
    • 各技術
    • 各用途
    • 各終端用戶
    • 各國
  • 南美:各國分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章 中東、非洲的精密精神醫學市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各生物標記
    • 各樣品
    • 各技術
    • 各用途
    • 各終端用戶
    • 各國
  • MEA:各國分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 埃及
    • 土耳其

第12章 市場動態

  • 促進因素
  • 課題

第13章 市場趨勢與開發

第14章 競爭情形

  • Altimate Healthcare
  • PsyProtix, Inc
  • Cerebral-Alto Nanoscience
  • Precision Psychiatric Services, Inc
  • Tempus Labs, Inc.
  • Curis AI Inc.

第15章 策略性建議

簡介目錄
Product Code: 12983

The global precision psychiatry market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include rise in incidences of mental health and technological advancements, which are bolstering the market growth, globally. Precision psychiatry is new field within precision medicine, which seeks to detect and capitalize on individual differences in biology, environment, lifestyle, and social determinants of health to improve mental health prevention, diagnosis, and treatment. The other factors supporting the market's growth are increasing awareness, growing investments, increase in population, changing lifestyle, decreasing cost of sequencing, increasing adoption of inorganic growth strategies and support from governments for healthcare infrastructure. Also, the high adoption of advanced molecular diagnostic technologies by the researchers to conduct genomic and proteomic analysis associated to the onset and manifestation of psychiatric illnesses are some of the key factors that are projected to bolster the market growth.

Increase in Prevalence of Mental Disorders

Over the past few years, rise in number of people suffering from mild or severe depressive disorders is seen. These mental illness or disorders are basically caused due to chemical, genetic, and anatomical conditions, or psychological origins such as trauma. Thus, to seek better lives for those suffering from mental illness, precision psychiatry is much required, which attributes to the growth of the market, globally. For instance, according to the National Institute of Mental Health, around one in every five U.S. adults suffer from mental illness. Also, in 2020, 25.8% of females were suffering from mental illness.

Increasing Adoption of Inorganic Growth Strategies

Increasing inorganic growth strategies by key players are expected to drive the global precision psychiatry market growth during the forecast period. For instance, in 2021, Alto Neuroscience announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. Similarly, in 2021, Atai Life Sciences, a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix, which is a precision psychiatry company.

Increased demand for Genomics as precision psychiatry

From past few years, genomic technologies have advanced the understanding of neuropsychiatric disorders. Genomics plays a significant part in the diagnosis of several genetic disorders. It has ample scope in precision psychiatry as it can advocate medical management constructed on the genetic face of a person with the help of clinical data and AI. It incorporates DNA sequencing methods, recombinant DNA, and bioinformatics for sequencing, assembling, and analyzing the structure and functions of genomes. Many severe mental illnesses, such as schizophrenia and bipolar disorder, are highly inherited, and have a complex pattern of inheritance. These diseases can be identified by using sequencing technology, which evaluates the rare genetic variants. With the use of sequencing technology, psychiatry can ultimately reshape by predicting disease risk and lead to better understanding of aetiology, prognosis, or treatment response. Moreover, the decrease in cost of sequencing is also a key factor to increase the growth of the market.

Market Segmentation

The global precision psychiatry market is segmented into biomarkers, sample, technology, application, end user, and company. Based on biomarker, the market is divided into genetic and protein. Based on sample, the market is divided into blood-based and non-blood-based. Based on non-blood-based, the market is further divided into saliva, urine, cerebral spinal fluid, and others. Based on technology, the market is divided into sequencing, polymerase chain reaction, microarray, immunoassay, and others. Based on application, the market is divided into Alzheimer's disease, Parkinson's disease, autism, depression, and others. Based on end user, the market is divided into hospital & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rise in incidences of mental illness in the country.

Market Players

Altimate Healthcare, PsyProtix, Inc, Cerebral-Alto Nanoscience, Precision Psychiatric Services, Inc, Tempus Labs, Inc., and Curis AI Inc. are some of the leading companies operating in the market.

Report Scope:

In this report, global precision psychiatry market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Precision Psychiatry Market, By Biomarker:

  • Genetic
  • Protein

Precision Psychiatry Market, By Sample:

  • Blood Based
  • Non-Blood-Based
    • Saliva
    • Urine
    • Cerebral Spinal Fluid
    • Others
    • Precision Psychiatry Market, By Technology:
  • Sequencing
  • Polymerase Chain Reaction
  • Microarray
  • Immunoassay
  • Others

Precision Psychiatry Market, By Application:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Autism
  • Depression
  • Others

Precision Psychiatry Market, By End User:

  • Hospital & Clinics
  • Academic & Research Institutions
  • Others

Precision Psychiatry Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in precision psychiatry market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Precision Psychiatry Market

5. Voice of Customer

6. Global Precision Psychiatry Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Biomarkers (Genetic v/s Protein)
    • 6.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 6.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 6.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 6.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 6.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 6.2.6. By Company (2021)
    • 6.2.7. By Region
  • 6.3. Product Market Map

7. North America Precision Psychiatry Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Biomarkers (Genetic v/s Protein)
    • 7.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 7.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 7.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 7.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 7.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Precision Psychiatry Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Biomarker
        • 7.3.1.2.2. By Sample
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Mexico Precision Psychiatry Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Biomarker
        • 7.3.2.2.2. By Sample
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Canada Precision Psychiatry Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Biomarker
        • 7.3.3.2.2. By Sample
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User

8. Europe Precision Psychiatry Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Biomarkers (Genetic v/s Protein)
    • 8.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 8.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 8.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 8.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 8.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Precision Psychiatry Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Biomarker
        • 8.3.1.2.2. By Sample
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Germany Precision Psychiatry Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Biomarker
        • 8.3.2.2.2. By Sample
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. United Kingdom Precision Psychiatry Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Biomarker
        • 8.3.3.2.2. By Sample
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. Italy Precision Psychiatry Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Biomarker
        • 8.3.4.2.2. By Sample
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Spain Precision Psychiatry Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Biomarker
        • 8.3.5.2.2. By Sample
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Asia-Pacific Precision Psychiatry Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Biomarkers (Genetic v/s Protein)
    • 9.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 9.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 9.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 9.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 9.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Precision Psychiatry Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Biomarker
        • 9.3.1.2.2. By Sample
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. India Precision Psychiatry Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Biomarker
        • 9.3.2.2.2. By Sample
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Korea Precision Psychiatry Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Biomarker
        • 9.3.3.2.2. By Sample
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User
    • 9.3.4. Japan Precision Psychiatry Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Biomarker
        • 9.3.4.2.2. By Sample
        • 9.3.4.2.3. By Technology
        • 9.3.4.2.4. By Application
        • 9.3.4.2.5. By End User
    • 9.3.5. Australia Precision Psychiatry Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Biomarker
        • 9.3.5.2.2. By Sample
        • 9.3.5.2.3. By Technology
        • 9.3.5.2.4. By Application
        • 9.3.5.2.5. By End User

10. South America Precision Psychiatry Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Biomarkers (Genetic v/s Protein)
    • 10.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 10.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 10.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 10.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 10.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Precision Psychiatry Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Biomarker
        • 10.3.1.2.2. By Sample
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Argentina Precision Psychiatry Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Biomarker
        • 10.3.2.2.2. By Sample
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Colombia Precision Psychiatry Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Biomarker
        • 10.3.3.2.2. By Sample
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Middle East and Africa Precision Psychiatry Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Biomarkers (Genetic v/s Protein)
    • 11.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 11.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 11.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 11.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 11.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Precision Psychiatry Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Biomarker
        • 11.3.1.2.2. By Sample
        • 11.3.1.2.3. By Technology
        • 11.3.1.2.4. By Application
        • 11.3.1.2.5. By End User
    • 11.3.2. Saudi Arabia Precision Psychiatry Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Biomarker
        • 11.3.2.2.2. By Sample
        • 11.3.2.2.3. By Technology
        • 11.3.2.2.4. By Application
        • 11.3.2.2.5. By End User
    • 11.3.3. UAE Precision Psychiatry Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Biomarker
        • 11.3.3.2.2. By Sample
        • 11.3.3.2.3. By Technology
        • 11.3.3.2.4. By Application
        • 11.3.3.2.5. By End User
    • 11.3.4. Egypt Precision Psychiatry Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Biomarker
        • 11.3.4.2.2. By Sample
        • 11.3.4.2.3. By Technology
        • 11.3.4.2.4. By Application
        • 11.3.4.2.5. By End User
    • 11.3.5. Turkey Precision Psychiatry Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Biomarker
        • 11.3.5.2.2. By Sample
        • 11.3.5.2.3. By Technology
        • 11.3.5.2.4. By Application
        • 11.3.5.2.5. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Altimate Healthcare
  • 14.2. PsyProtix, Inc
  • 14.3. Cerebral-Alto Nanoscience
  • 14.4. Precision Psychiatric Services, Inc
  • 14.5. Tempus Labs, Inc.
  • 14.6. Curis AI Inc.

15. Strategic Recommendations